What's just happened?

The government will restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland. 

How long will this ban last?

This emergency ban will last from 3 June to 3 September 2024 and no new patients under 18 will be prescribed these medicines (medicinal products that consist of or contain buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin) for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. 

Read more: Passing the mic to transgender patients

Who does the ban apply to?

This ban will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland. 

Why has it been introduced?

The NHS stopped the routine prescription of puberty blocker treatments to under-18s following the Cass Review into gender identity services.

In April 2024, the GPhC provided an interim update for pharmacists and pharmacy teams on this topic, following the  publication of  the Cass Review in April 2024. 

This indicated that they were continuing to consider the Cass Review to consider any communications or other actions they should take in response.  

What happened next?

This was followed by a further resource on 24 May 2024 to support pharmacists and pharmacy technicians if they are providing pharmacy services to children and young people relating to gender incongruence. 

This resource provides a number of questions for pharmacy professionals to consider which cover professional behaviour, personal values and beliefs, professional judgement, supporting vulnerable or at-risk patients, consent, confidentiality and effective communication, and clinical appropriateness of medicines.

What should I do if asked to fill a prescription for puberty blockers?

This is an area of great public interest and pharmacists should be extremely careful if they receive prescriptions for these medications and ensure that they are up to date with the latest resources from the GPhC. 

There is a very clear expectation by the regulator that pharmacy professionals have taken into account the evidence that informed the work of the Cass Review and the review’s findings about the ‘lack of high-quality evidence’ in this area. 

We advise pharmacy professionals should keep clear and detailed contemporaneous documentation concerning these medications, including when dispensing is not appropriate.

Richard Hough is a partner and head of Healthcare at Brabners LLP, and a former pharmacist.